23 December, 2021
The Hospital Clínic Group develops a second CAR-T, suitable for multiple myeloma resistant to treatment
The Hospital Clínic Group of Barcelona along with the August Pi and Sunyer Biomedical Research Institute (IDIBAPS) have developed a new CAR-T, the ARI-0002h, for patients with multiple myeloma resistant to habitual treatments. The results of a clinical trial, recently presented in the American Society of Hematology (ASH), which was held in Atlanta, have demonstrated that this new CAR-T for multiple myeloma is capable of getting a response rate of up to 75% after a year of treatment and that in 60% of patients that have complete remission and without residual disease, results that are, without doubt, very hopeful.
16 February, 2021
The AEMPS approves the use of a CAR-T therapy developed by the Hospital Clínic Group for the treatment of a type of leukaemia
In recent years, cancer treatment has been revolutionised by immunotherapy, an approach that uses a patient’s own immune system to attack tumour cells. The Spanish Agency of Medicines and Medical Devices (AEMPS) has just approved ARI-0001, a CAR T-cell therapy (a type of immunotherapy) developed entirely by the Hospital Clínic Group, for use as a medicinal product. This is the first time that a treatment with genetically modified cells developed entirely in Europe has been approved by a regulatory agency, and it is also the first time that it has been done without the backing of a pharmaceutical company.
